• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acadia Pharmaceutica (NQ: ACAD )

14.81 +0.22 (+1.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acadia Pharmaceutica

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
August 04, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Biotech Investors: August's Key PDUFA Catalysts You Must Know
July 31, 2022
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the... 
Via Benzinga
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 33% Today?
June 21, 2022
Today, investors in Acadia Pharmaceuticals and ACAD stock are in selling mode. The FDA gave a thumbs down on a key drug. 
Via InvestorPlace
Why Acadia Pharma Shares Are Plunging Today
June 21, 2022
Via Benzinga
Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022
July 25, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
July 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap of Monday's Biotech Catalysts - End of the Day Summary
July 18, 2022
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least... 
Via Benzinga
Why ACADIA Pharmaceuticals Shares Are Trading Higher Today?
June 15, 2022
Via Benzinga
Acadia Seeks FDA Approval For Genetic Neurological Disorder Candidate
July 18, 2022
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for trofinetide for the treatment of Rett syndrome. 
Via Benzinga
Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
July 18, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
Where ACADIA Pharmaceuticals Stands With Analysts
July 11, 2022
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter: 
Via Benzinga
Analysts Try To See Beyond Acadia's Alzheimer's Disease Psychosis
June 21, 2022
HC Wainwright says that a negative AdCom vote on Acadia Pharmaceuticals Inc&# 
Via Benzinga
Nasdaq Rises 2.5%; ACADIA Pharmaceuticals Shares Plummet
June 21, 2022
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 2.5% on Tuesday. 
Via Benzinga
67 Biggest Movers From Yesterday
June 22, 2022
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital. 
Via Benzinga
Dow Jumps 550 Points; Convey Health Solutions Shares Spike Higher
June 21, 2022
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 550 points on Tuesday. 
Via Benzinga
45 Stocks Moving In Tuesday's Mid-Day Session
June 21, 2022
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.8% to $10.31 as the company agreed to be taken private by TPG Capital,. 
Via Benzinga
U.S. Markets Open Higher; Lennar Earnings Top Views
June 21, 2022
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 500 points on Tuesday. 
Via Benzinga
Acadia Pharmaceuticals Crashes After FDA Panel Votes Down Its Alzheimer's Psychosis Drug
June 21, 2022
It's not looking good for Nuplazid in Alzheimer's disease psychosis. 
Via Investor's Business Daily
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
June 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
June 21, 2022
Goldman Sachs cut SunPower Corporation. (NASDAQ: SPWR) price target from $19 to $13. SunPower shares fell 3.1% to $17.37 in pre-market trading. 
Via Benzinga
Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
June 17, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease
June 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Acadia Pharmaceuticals Stock Trading Halted Today
June 17, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate
June 16, 2022
HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected. 
Via Benzinga
Why Acadia Pharma Surged Despite A Negative FDA Take On Its Lead Drug
June 15, 2022
There were no surprises in the FDA's assessment of an Alzheimer's drug from Acadia Pharmaceuticals, and ACAD stock surged Wednesday. 
Via Investor's Business Daily
5 Biotech Stocks To Watch During The Week Of June 13
June 13, 2022
Biotech stocks continued to be under pressure in the past week amid broader market weakness, precipitated by economic worries. Company-specific developments also triggered downward moves. Here's a... 
Via Benzinga
71 Biggest Movers From Yesterday
June 16, 2022
Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares jumped 225% to close at $4.68 on Wednesday after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration... 
Via Benzinga
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
June 03, 2022
These biotech stocks face some key make-or-break events in June that could have big implication for their futures. 
Via InvestorPlace
55 Stocks Moving In Wednesday's Mid-Day Session
June 15, 2022
Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares surged 92.4% to $2.77 after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration Extravehicular Activity... 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap